Redx Pharma has struck a deal with a fellow a Cheshire company to supply its Porcupine inhibitor – which tackles hard-to-treat cancers for clinical trials.
Porcupine (RXC004) battles pancreative, triple negative breast and head and neck cancers. First in-human studies are expected to start early in 2017.
The deal is with Quay Pharma which will manufacture RXC004.
The novel, potent small molecule Porcupine inhibitor targets the Wnt pathway, an embryonic signalling pathway implicated in the maintenance of cancer stem cells associated with tumorigenesis, metastasis, recurrence and resistance in several types of cancer.
Neil Murray, chief executive of Redx, said: “We are pleased to confirm that we remain on track to enter the clinical trial phase for our Porcupine program in the first quarter of 2017. Our Porcupine inhibitor is an especially exciting clinical candidate, both scientifically and commercially.”
See the article in full at BusinessDesk.com